Non–vitamin K antagonist anticoagulants (NOACs) have been used to prevent
thromboembolism in patients with atrial fibrillation (AF) and shown favorable clinical …

Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Background Although randomized controlled trials (RCTs) indicated that standard dose non–
vitamin K antagonist oral anticoagulants (NOACs) were more compelling, low dose NOACs …

Background: Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as
alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for …

The role of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention
remains unclear in Asian patients with atrial fibrillation (AF). Therefore, we performed a meta …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are effective and safe
alternatives compared with vitamin K antagonists (VKAs) for thromboembolic prevention in …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …